Intravitreal ranibizumab for choroidal neovascularisation secondary to pathologic myopia: 12 month results.
Rajendram
R
R
Costa-Gomes
N
N
Horgan
S E
SE
D000367:Age Factors; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D058449:Intravitreal Injections; D009216:Myopia / Q000150:complications* / Q000175:diagnosis; D000069579:Ranibizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069579:Ranibizumab